

Product datasheet for **SR323917**

PD-L1 (CD274) Human siRNA Oligo Duplex (Locus ID 29126)

Product data:

Product Type:	siRNA Oligo Duplexes
Purity:	HPLC purified
Quality Control:	Tested by ESI-MS
Sequences:	Available with shipment
Stability:	One year from date of shipment when stored at -20°C.
# of transfections:	Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM).
Note:	Single siRNA duplex (10nmol) can be ordered.
RefSeq:	NM_001267706 , NM_001314029 , NM_014143 , NR_052005
UniProt ID:	Q9NZQ7
Synonyms:	B7-H; B7H1; hPD-L1; PD-L1; PDCD1L1; PDCD1LG1; PDL1
Components:	CD274 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 29126) Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol Included - SR30005, RNase free siRNA Duplex Resuspension Buffer - 2 ml
Summary:	This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).